Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19826871 | 0.86 | KMT2A (0.54) | MEN1KMT2ACYP19A1MAPTCA12 | |
| SCHEMBL13973215 | 0.82 | CA1 (0.50) | CYP19A1MAPTCYP1A2CA9ALDH1A1 | |
| SCHEMBL13959189 | 0.81 | CA2 (0.49) | CYP19A1CYP1A2CYP3A4CA9ALDH1A1 | |
| SCHEMBL14458145 | 0.81 | CNR1 (0.51) | CYP19A1CA9L3MBTL1ALDH1A1 | |
| SCHEMBL27950175 | 0.78 | CA9 (0.71) | MEN1KMT2ACYP19A1MAPTCA12 | |
| SCHEMBL14902028 | 0.78 | MEN1 (0.71) | MEN1KMT2ACYP19A1CA12CYP1A2 | |
| SCHEMBL6799664 | 0.78 | CYP19A1 (0.59) | MEN1KMT2ACYP19A1CA9ALDH1A1 | |
| SCHEMBL10228577 | 0.77 | PSEN1 (0.56) | MEN1KMT2AMAPTCYP3A4ALDH1A1 | |
| SCHEMBL18980588 | 0.75 | KMT2A (0.62) | MEN1KMT2ACYP19A1MAPTCA12 | |
| SCHEMBL18371676 | 0.75 | ALDH1A1 (0.50) | MEN1KMT2ACYP19A1MAPTCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109098-A1 | METHOD FOR PREPARING BENZYLAMINE DERIVATIVE THROUGH AMINATION OF BENZYLIC C-H BOND UNDER VISIBLE LIGHT-INDUCED NICKEL CATALYSIS | SHANGHAI OURCHEM BIO-TECHNOLOGY CO., LTD. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2024164666-A1 | METHOD FOR PREPARING BENZYLAMINE DERIVATIVE BY VISIBLE LIGHT-PROMOTED NICKEL-CATALYZED AMINATION OF BENZYL C-H BONDS | 上海沃凯生物技术有限公司 | 2024-08-15 | — | — | WO | disclosed |
| CN-116063209-B | Method for preparing benzylamine derivative by catalyzing amination of benzyl C-H bond through nickel under promotion of visible light | 上海沃凯生物技术有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-116063209-A | Method for preparing benzylamine derivative by catalyzing amination of benzyl C-H bond through nickel under promotion of visible light | 上海沃凯生物技术有限公司 | 2023-05-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109098-A1 | METHOD FOR PREPARING BENZYLAMINE DERIVATIVE THROUGH AMINATION OF BENZYLIC C-H BOND UNDER VISIBLE LIGHT-INDUCED NICKEL CATALYSIS | HRH3, HRH4, HRH2 | MEN1 985/4885KMT2A 496/4885CYP19A1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.